As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...